(Japan) Introduction to Cancer Vaccines
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Cancer vaccine therapy — including immune checkpoint inhibitors — is an important category of cancer immunotherapy. Current approaches target antigens such as MAGE, gp100, WT1, and NY-ESO using peptide vaccines, nucleic acid vaccines, and cellular vaccines. In recent years, particular attention has been given to neoantigen-based vaccines, which target highly specific tumor antigens unique to individual patients. Adjuvants that enhance immune response have also attracted significant research interest, especially as some earlier approaches showed limited efficacy and had their studies discontinued.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4